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Introduction {#sec1}
============

The humoral immune response protects against pathogens through mechanisms such as antibody-mediated neutralization, opsonization, antibody-dependent cellular cytotoxicity, and initiation of the classical complement pathway ([@bib13]). The quality and/or magnitude of the antibody response is an important correlate of protection against many pathogens, including viruses such as influenza A virus (IAV) and severe acute respiratory syndrome coronavirus (SARS-CoV) ([@bib7], [@bib61]). IAV is a particularly large public health burden, with seasonal IAV strains incurring significant morbidity and mortality annually (estimated 50 million cases, 1 million hospitalizations, and 80 thousand deaths in the 2017-2018 season) ([@bib4]). Though vaccination is an important component of influenza control, existing influenza vaccines often exhibit low efficacy. While this is partially due to antigenic mismatch between vaccines and circulating influenza strains ([@bib31]), numerous studies have shown that some individuals fail to mount a sufficient protective antibody response upon vaccination ([@bib68]).

Multiple factors contribute to variation in an individual's ability to mount protective antigen-specific antibody responses following infection or vaccination. These factors include age, underlying disease states, and prior exposure history to related pathogens or vaccines ([@bib31]). Despite some dissent ([@bib3]), multiple studies across different pathogens and vaccines indicate that antibody responses have a strong heritable component, with many estimates of ∼50% ([@bib28], [@bib35], [@bib47]). In the case of the measles vaccine, the antibody response was nearly 90% heritable, suggesting that genetics are a predominant factor contributing to interindividual variation in vaccine response ([@bib64]). Despite this strong evidence for the role of genetic variation in modulating antibody response, the genetic factors regulating antibody response to IAV are unknown. Complicating this type of analysis is the fact that antibody response is the downstream result of a complex immunological process involving multiple tissues, cell types, and cell signaling pathways. Genes underlying variation in antibody response may be involved in any stage of the response, from general regulatory aspects of B cell development to more IAV-specific effects such as innate immune sensing. An understanding of naturally polymorphic genes involved in the antibody response, how they function, and whether their effects are broad or pathogen specific could lead to improved vaccine design, such as by utilization of adjuvants that specifically target relevant pathways and boost antibody response.

Despite the importance of understanding genetic regulation of pathogen-specific immune responses, identifying and studying genetic determinants of host antibody responses or other aspects of immunity is challenging in humans. Demographic and environmental factors such as viral dose and prior immune history affect immune responses to infection or vaccination ([@bib31]) and confound analyses. Furthermore, a lack of replicates in outbred humans, as well as difficulties accessing relevant tissues, presents challenges for phenotyping and mechanistic validation. Historically, mouse models have been used to overcome many of the logistical, experimental, and ethical issues that confound human studies. The genetic tractability of the mouse genome, including the ready availability of many gene-specific knockouts, and the ability to easily generate new knockouts, has provided key insights into the host pathways that control both development of the immune system and the quality and durability of vaccine-induced immunity ([@bib32], [@bib67]). Increasingly, it is appreciated that standard laboratory mouse strains do not recapitulate the genetic diversity observed in the outbred human population ([@bib56]), and this lack of diversity has limited the utility of the mouse in identifying polymorphic genes and pathways that contribute to the variation in the adaptive immune responses observed in humans.

The Collaborative Cross (CC), a multi-parental mouse genetic reference population, was developed to serve as a representative mammalian model of population-wide genetic diversity while still providing the experimental tractability of the reproducible inbred mouse ([@bib6]). CC strains have fixed and known genomes, facilitating genetic mapping to identify quantitative trait loci (QTLs) driving phenotypes of interest ([@bib23]). Studies across multiple pathogens have highlighted the utility of the CC for studying infectious disease outcomes; CC mice show disease phenotypes as diverse as their genetics, facilitating discovery of novel and extreme phenotypes as well as in QTL mapping (reviewed in [@bib46]). Furthermore, use of the CC enables analysis of correlations between mapped QTL and additional phenotypes across studies, extending the ability to interpret the breadth of phenotypic effect of mapped loci beyond the context in which they were originally mapped. Relevant to this study, CC mice display a wide range of phenotypes in response to challenge with IAV ([@bib12], [@bib25], [@bib39]) as well as variation in antibody glycosylation ([@bib26]).

To investigate the impact of host genetic variation on the humoral immune response to IAV, we evaluated IAV-specific antibody responses over a broad infection time course across a large set of F1 crosses between CC strains (CC-F1s). We observed significant variation in antibody response to IAV across these CC-F1s, including variation in the magnitude and kinetics of virus-specific immunoglobulin M (IgM) and IgG, as well as IgG subtype composition, and found these responses were highly heritable. We identified multiple genetic loci associated with variation in specific antibody subtypes at and across different time points post-infection. We highlight the most significant and interpretable loci, show that they have robust effects on antibody responses to other viruses, and identify candidate genes for each.

Results {#sec2}
=======

Antibody Response to IAV Varies across Genetically Diverse Mice {#sec2.1}
---------------------------------------------------------------

To study the role of genetic factors in driving the magnitude, kinetics, and composition of the antibody response to IAV, we measured IAV hemagglutinin (HA)-specific antibody levels (henceforth referred to as IAV-specific antibody) in a large population of F1 crosses between CC strains (N = 116). This population provided a reproducible population of heterozygous animals to mimic the genetic heterozygosity of the human population (see [Data S1](#mmc2){ref-type="supplementary-material"} for full list of the F1s with complete strain names including laboratory codes). Our analysis focused on HA-specific antibody responses, as the bulk of the anti-IAV antibody response is directed against the HA protein, and HA-specific antibody responses are most correlated with protective neutralization ([@bib22]). Female mice from 116 CC-F1s were infected intranasally with IAV A/CA/04/09 (H1N1) and sacrificed at multiple time points post-infection (3 mice per CC-F1 at each time point for a total of ∼1,350 mice). IAV-specific antibody was measured from animals sacrificed at days 7, 10, 15, and 45 post-infection to capture both early and late humoral immune responses. IgM, IgG1, IgG2a+IgG2c (combined detection of subtypes that segregate across mouse strains ([@bib74])), IgG2b, IgG3, and total IgG were quantified from each animal (a total of ∼8,000 antibody measurements across the 116 CC-F1s and 4 time points) to capture differential dynamics of individual antibody subtypes and isotypes across our infection time course.

Overall, IAV-specific antibody kinetics largely matched expected patterns. On average, IgM levels peaked early and then declined, while IgG levels increased throughout our time course ([Figure 1](#fig1){ref-type="fig"} A). However, as shown in [Figure 1](#fig1){ref-type="fig"}C, individual F1s varied in overall levels and kinetics of the IAV-specific antibody response, with some F1s displaying responses that were much more rapid and/or greater in magnitude than others (e.g., CC018xCC009 versus CC036xCC051). A number of F1s showed abnormal IgM responses, with later peaks (e.g., at day 15, CC012xCC038 and CC032xCC017) or increasing through day 45 (e.g., CC011xCC032; [Figure 1](#fig1){ref-type="fig"}D). Other F1s were particularly notable outliers more generally across isotypes. For example, excluding its' IgG1 levels, CC003xCC062 showed some of the highest magnitude antibody responses at day 45 across isotypes ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1The CC-F1 Population Exhibits Broad Between-Strain Variation in the Magnitude, Kinetics, and Composition of IAV-Specific Antibody Responses(A) The CC-F1 population generally exhibited an overall pattern of antibody responses that is consistent with canonical antibody maturation (e.g., IgM peaking early and then waning, concurrent with a continual expansion of IgG isotypes). Bar heights represent mean raw area under the curve (AUC) values across all CC-F1s.(B) The correlation structure of antibody isotypes and subtype responses in the F1s over time was evaluated to determine the relationship between the development of various antibody types across the population.(C and D) Representative examples of variation in the magnitude and kinetics of IgG (C) and IgM (D), with some exceptionally notable outliers for IgM. Each point represents an individual mouse, and bars represent mean values for F1s. (D). This variation was independent of *Mx1* haplotype (for both panel sets red = *Mx1 −/−*, blue = *Mx1* +/−).See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

We next investigated the relationships between antibody subtypes across the time points. Correlations between individual subtypes at different time points were largely driven by temporal kinetics, aside from IgM and some IgG1 responses that cluster independently ([Figure 1](#fig1){ref-type="fig"}B). Interestingly, antibody composition on days 7 and 15 clustered most similarly, followed by day 45 and lastly day 10. This clustering suggests that day 10 may represent a unique inflection point in the antibody response across the CC population, as opposed to a natural continuation of the responses between days 7 and 15.

We also evaluated whether virus-induced disease correlated with the antibody response. Similar to the variation in antibody response ([Figure 1](#fig1){ref-type="fig"}), CC-F1s exhibited a wide range of disease outcomes following IAV infection, ranging from asymptomatic to severe weight loss and mortality ([Figure S2](#mmc1){ref-type="supplementary-material"}). We have previously shown that these differences in disease susceptibility can largely be attributed to variation in the IAV resistance gene *Mx1* ([@bib39]), although other smaller effect loci also contribute to variation in IAV susceptibility ([@bib12]). Given the role of *Mx1* in regulating both disease susceptibility and viral load, we assessed whether *Mx1* haplotype correlated with the antibody response. Protective *Mx1* haplotypes (associated with decreased viral load and weight loss) showed some relationship with decreased antibody response throughout infection, with the strongest relationship seen early in infection (days 7 and 10) and with IgG1 and IgG3 ([Table S1](#mmc1){ref-type="supplementary-material"}). However, these relationships waned over time and were not sufficient to fully explain the variation in antibody responses we observed throughout our study. In order to further clarify the role of *Mx1* and viral load in influencing antibody responses, we measured viral load by genome copy assay at day 2 post-infection for a subset of CC-F1s selected for either high or low IgG responses at day 10 post-infection. We observed no trend between viral load and IgG levels on any day post-infection ([Figure S3](#mmc1){ref-type="supplementary-material"}). We also assessed whether the antibody response was associated with IAV-induced disease as measured by maximal weight loss, with control for *Mx1* haplotype. We observed correlations between maximal weight loss and the IgG1 response across time points, in addition to with early IgM and late total IgG ([Table S2](#mmc1){ref-type="supplementary-material"}), with increased antibody levels associated with enhanced weight loss. These observations suggest that there is a relationship between antibody response and the severity of virus-induced disease that is independent of *Mx1*-mediated effects.

Genetic Mapping Identifies Loci Associated with Variation in Virus-Specific Antibody Response {#sec2.2}
---------------------------------------------------------------------------------------------

IAV-specific antibody responses were significantly influenced by genetic factors across isotypes/subtypes and time points, with heritability estimates ranging from 26%--72% (median 44%; [Table S1](#mmc1){ref-type="supplementary-material"}). This roughly aligns with estimates reported in human studies of antibody responses ([@bib24]). Antibody responses were least heritable at day 7 (39% average across isotypes) and most heritable at day 45 (57% average across isotypes), suggesting that the early antibody response is more driven by stochastic factors, while genetic factors play a progressively more important role later in the antibody response. The exception to this trend was IgM, which was most heritable at day 7 (56%), fitting with the classical kinetic profile of the IgM response.

Given the high heritability of these antibody phenotypes, we performed genetic mapping to identify QTLs (genomic regions in which genotypes correlate with a phenotype of interest) associated with variation in antibody response. We performed genetic mapping on both total amount of antibody isotypes/subtypes at single time points (i.e., days 7, 10, 15, and 45 individually) in addition to the kinetics (slope) between adjacent time points (i.e., between days 7 and 10, 10 and 15, and 15 and 45) to identify genetic factors contributing to variation in the overall magnitude, composition, and kinetics of the antibody response. Significant (genome-wide p \< 0.05) and suggestive (genome-wide p \< 0.1) QTLs are summarized in [Table 1](#tbl1){ref-type="table"} (see also [Table S3](#mmc1){ref-type="supplementary-material"} for additional suggestive QTLs where p \< 0.2). In total, we mapped 2 significant QTLs and 21 suggestive QTLs for antibody response to influenza (*Ari1*--*Ari23*) ([Figure 2](#fig2){ref-type="fig"} ).Table 1Significant and Suggestive (p \< 0.1) QTLsNameDayPhenotypeChrp ValueStart (Mb)Max (Mb)End (Mb)Haplotype Effects*Ari1*7IgG2a+IgG2c177.65E-024752.654.4low: NOD, WSB*Ari2*10IgG3112.80E-0269.171.772.6low: WSB*Ari3*15IgM88.15E-02108.7109.4113.1high: WSB*Ari4*15--45IgG2b53.95E-0236.838.745.3high: B6, NOD, NZO, PWKlow: AJ, 129, CAST, WSB*Ari5*15IgG1168.00E-024040.644.7high: CAST, PWKlow: AJ*Ari6*15IgG2b79.65E-02109.1114.3115.5high: NZO*Ari7*45IgG397.35E-027.813.522.3high: 129, NZO, CASTlow: AJ, B6, NOD, PWK*Ari8*15--45TotalG159.45E-0251.653.255high: PWKlow: CAST[^3]Figure 2Multiple Loci Drive Antibody Responses to IAVQTL mapping allowed us to identify 23 loci contributing to the antibody response composition, magnitude, and kinetics. We summarize these loci (*Ari1*--*Ari23*) in a chromosomal ideogram showing their positions, as well as the antibody type and the time point for which they were mapped on their corresponding genomic loci.

The majority of QTLs were mapped for individual subtypes at given time points (16 QTLs) compared with responses between time points (7 QTLs). At individual time points, the number of QTLs mapped tracked with heritability, progressively increasing from earlier to later time points (2 at day 7, 4 at day 10, 4 at day 15, and 6 at day 45) ([Table S4](#mmc1){ref-type="supplementary-material"}). For kinetic measurements, the majority of QTLs were mapped between days 15 and 45 (1 between days 7 and 10, 1 between days 10 and 15, and 5 between days 15 and 45). IgM, the least abundant isotype, was mapped least frequently (1 QTL), while IgG2a+IgG2c, the most abundant subtype, was mapped most frequently (6 QTLs). The rest of the subtypes (IgG1, IgG2b, and IgG3) and total IgG were each mapped 4 times ([Table S5](#mmc1){ref-type="supplementary-material"}). We identified evidence for complex architecture of specific responses (same phenotype, multiple QTLs), as illustrated by *Ari1* and *Ari8,* which were both mapped for IgG2a+IgG2c at day 7 ([Tables 1](#tbl1){ref-type="table"} and [S3](#mmc1){ref-type="supplementary-material"}). While QTLs were largely mapped across many chromosomes, we also found evidence for pleiotropy (same QTL, multiple phenotypes), as evidenced by the overlap between *Ari14-16* on chromosome 5. Importantly, none of the QTL mapped to the *Mx1* locus, which further supports the idea that, while *Mx1* alleles may have some relationship with antibody responses ([Table S1](#mmc1){ref-type="supplementary-material"}), the genetic regulation of the IAV-specific antibody response is predominantly independent of *Mx1*.

We prioritized QTLs for follow-up candidate gene analysis based on their genome-wide significance as well as clarity of haplotype effects. From the 8 QTLs with p \< 0.1, we focused on 4 QTLs, *Ari1*--*Ari4* ([Figure 3](#fig3){ref-type="fig"} ). *Ari1* (chromosome 17 \[chr17\]: 46.1--54.5 Mb, p = 0.0765) was mapped for IgG2a+IgG2c at day 7 post-infection and accounts for 4.5% of the total phenotypic variation (15.2% of heritable variation), driven by a low response from F1s with WSB/EiJ and NOD/ShiLtJ haplotypes at the locus. *Ari2* (chr11: 69.1--72.6 Mb, p = 0.028) was mapped for IgG3 at day 10 post-infection and accounts for 9.8% of the total phenotypic variation (30.7% of heritable variation), driven by a low response from F1s with a WSB/EiJ haplotype at the locus. *Ari3* (chr8: 108.7--113.1 Mb, p = 0.0815) was mapped for IgM at day 15 post-infection and accounts for 5.8% of the total phenotypic variation (14.8% of the heritable variation), driven by a high response from F1s with a WSB/EiJ haplotype at the locus. Finally, *Ari4* (chr5: 37.0--46.1 Mb, p = 0.0395) was mapped for change in IgG2b between days 15 and 45, with less change between time points in F1s carrying 129S1/SvImJ, A/J, CAST/EiJ, and WSB/EiJ haplotypes at the locus.Figure 3Representative *Ari* QTLs Associated with Variation in IAV-Specific Antibody Responses(A--C) show *Ari1*, D--F show *Ari2*, G--I show *Ari3*, and J--L show *Ari4*.(A, D, G, and J) Phenotypic distributions for the traits mapped to *Ari1*--*Ari4*, respectively. Each plot is independently ordered by the CC-F1 means for that trait (black points) and also shows the individual mice (purple points). The exception is (J), which only shows mean values, as the ratios of antibody response between time points were calculated using the mean value for each F1 at the relevant individual time points.(B, E, H, and K) show the associated QTL LOD plots (significance score across the genome) for *Ari1*--*Ari4*. Significance thresholds are shown in red (genome-wide p = 0.05), blue (p = 0.1), and green (p = 0.2). Following identification of QTLs, we determined the causal haplotypes driving these responses (C, F, I, and L). Each plot is zoomed in to the relevant QTL loci on the x axis. The lower black line shows the LOD score for that region, and the colored lines display the estimated effect of each of the 8 CC founder haplotypes (A/J = yellow, C57BL/6J = gray, 129S1/SvImJ = pink, NOD/ShiLtJ = dark blue, NZO/HlLtJ = light blue, CAST/EiJ = green, PWK/PhJ = red, and WSB/EiJ = purple). Causal haplotype groups are determined based on direction and distance from mean effect and the largest split distance between lines (e.g., in I, the WSB line is furthest away from all others).

Antibody response loci may be specifically associated with the mapped phenotype of interest (e.g., IAV-specific IgG3) or reflect a broader effect on immune system development or response. Therefore, we interrogated the extent to which *Ari1*--*Ari4* haplotypes further correlated with other aspects of IAV-induced pathology or immune responses in our CC-F1 population. We reduced the number of states being analyzed from the 8 independent founder haplotypes used in our QTL mapping analysis to the 2 variant haplotype groups (e.g., high or low response) at the locus, thereby enhancing power to detect less strong phenotypic associations. None of the *Ari* loci showed correlations with gross IAV-induced disease as measured by weight loss, with control for *Mx1* haplotype ([Table S4](#mmc1){ref-type="supplementary-material"}).

The *Ari* loci showed numerous significant correlations with additional IAV-specific antibody isotypes and time points. *Ari1* (IgG2a+IgG2c, day 7) showed broad correlations across multiple isotypes at days 7, 10, and 15. Additionally, the association between *Ari1* and IgG1 persisted through day 45 ([Table S1](#mmc1){ref-type="supplementary-material"}). This suggests that *Ari1* plays a role in the early antibody response that carries over through the mid-stage response, with a unique persistent effect on IgG1. *Ari2* (IgG3, day 10) was broadly correlated with the antibody response at day 7 but showed the strongest correlations at day 10 and was also associated with total IgG through days 15 and 45 ([Figure 4](#fig4){ref-type="fig"} ), suggesting that *Ari2* broadly impacts the overall early antibody response with some prolonged effect. *Ari3* (IgM, day 15) also broadly correlated with the antibody response at day 7, including a strong correlation with total IgG. *Ari3* was correlated with IgG2a+IgG2c and total IgG day 15 post-infection, suggesting that *Ari3* is a driver in the early-to-mid stage antibody response for both IgG and IgM ([Table S1](#mmc1){ref-type="supplementary-material"}). When tested across individual time points, *Ari4* (IgG2b, ratio between days 15 and 45) showed associations with multiple isotypes, including IgG2b, at day 15, but not day 45 ([Table S1](#mmc1){ref-type="supplementary-material"}), indicating that the association between *Ari4* and temporal changes in IgG2b levels are predominantly driven by effects on antibody isotype levels on day 15.Figure 4*Ari2* Shows Broad Effects on IAV-Specific Antibody Responses in the CC-F1 PopulationWe assessed the impact that a WSB/EiJ haplotype (x axis; 1 = one WSB haplotype; 2 = two non-WSB haplotypes) have on other IAV antibody responses in this study (y axis: CC-F1 mean levels of transformed AUC levels for given isotypes/time points). Points represent mean values for CC-F1s, with \~3 mice per CC-F1. Annotations refer to transformations applied to datasets (^∗^p \< 0.1, ^∗∗^p \< 0.05, ^∗∗∗^p \< 0.01).See also [Table S1](#mmc1){ref-type="supplementary-material"}.

To further assess the role of *Ari1*--*Ari4* in virus-specific antibody responses, we tested to see if *Ari1*--*Ari4* haplotypes were associated with antibody responses to other viruses. For this analysis, we took advantage of existing datasets from related but independent studies with SARS-CoV, a respiratory virus, and chikungunya virus (CHIKV), an arbovirus. In the SARS-CoV study, mice from a similar panel of CC-F1s were infected with SARS-CoV, and antibody response to the spike (S) protein was measured at days 7, 15, and 29 post-infection. An additional measurement was taken 4 days following a secondary challenge ("rechallenge"), which was administered at day 28 post-primary infection. *Ari1* haplotypes were not associated with SARS-CoV-specific antibody responses ([Table S6](#mmc1){ref-type="supplementary-material"}). In contrast, *Ari2* haplotype showed broad associations with antibody specific to SARS-CoV at days 7 and 29, and with IgM at all time points post-primary and secondary challenge ([Table S6](#mmc1){ref-type="supplementary-material"}). *Ari3* haplotype showed only a few correlations with SARS-CoV antibody, which were not indicative of trends either across isotypes or time points ([Table S6](#mmc1){ref-type="supplementary-material"}). *Ari4* showed the strongest correlations with the SARS-CoV-specific antibody response, most potently at day 7 but lasting through days 15 and 29 ([Table S6](#mmc1){ref-type="supplementary-material"}). In the CHIKV study, mice from a panel of 64 inbred CC strains were infected with CHIKV. Virus-specific IgM, IgG, and neutralizing antibody were measured at day 7 post-infection. While *Ari1*, *Ari2*, and *Ari4* did not correlate with the CHIKV-specific antibody response (IgM, IgG, and neutralization titer) in CC-RI mice at day 7 post-infection, *Ari3* haplotypes showed strong associations with the CHIKV antibody response ([Table S6](#mmc1){ref-type="supplementary-material"}). Interestingly, these associations were in the opposite direction as observed for IAV (i.e., WSB/EiJ haplotype associated with decreased antibody response). Overall, these findings suggest that *Ari1* is uniquely associated with variation in IAV-specific antibody responses, while *Ari2*--*Ari4* show broader effects on virus-specific antibody responses. *Ari2* and *Ari4* are associated with variation in SARS-CoV-specific antibody responses, while *Ari3* was also found to be strongly associated with variation in the CHIKV-specific antibody response.

Candidate Gene Analysis {#sec2.3}
-----------------------

To identify candidate genes at each of the loci, we applied a series of criteria to filter through the variants ([Figure 5](#fig5){ref-type="fig"} ). We first conducted association testing as implemented in the R package DOQTL ([@bib15]), comparing the pattern of single-nucleotide polymorphisms (SNPs) at each marker within the QTL to the observed haplotype effects at the corresponding location, and filtering out variants below the LOD threshold. Next, candidate SNPs were categorized based on the classification of the affected genetic element (e.g., regulatory region, protein-coding gene, or non-coding RNA). While variation in regulatory regions, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), or other genetic elements may drive QTLs, we focused on SNPs in protein-coding genes for our analysis, as they have more interpretable and better defined functional consequences. The protein-coding genes at each locus were next evaluated based on whether the gene exhibited baseline expression in the lung or immune tissue (i.e., spleen or thymus) utilizing ENCODE data ([@bib71]).Figure 5Pipeline to Narrow Down Candidate Genes under *Ari1*--*Ari4*Variants under each QTL were considered if they were above the association testing threshold and were contained in a protein-coding gene. Protein-coding genes were then evaluated based on whether they were expressed in the lung or immune tissue. Using a separate transcriptional dataset from 11 CC strains infected with H3N2 influenza, IAV-specific and haplotype-specific differential expression was evaluated. Genes were considered if they had non-synonymous coding variants or splice region variants or showed haplotype-specific expression.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S7](#mmc1){ref-type="supplementary-material"}.

We next evaluated candidate genes based on the predicted consequences of their variants, which were determined using the Ensembl Variant Effect Predictor ([@bib40]). Genes with non-synonymous coding variants and splice variants were included as candidates. To assess the relevance of non-coding variants, which were determined most likely to have a role in differential expression, we leveraged transcriptional datasets from lungs and peripheral blood of 11 CC strains, which were either mock-infected or infected with IAV H3N2 (days 3 and 5 post-infection for lung; days 3, 5, and 8 for blood). We applied this data to assess if genes with non-coding variants were differentially expressed between haplotype groups (see examples in [Figure S4](#mmc1){ref-type="supplementary-material"}). By applying these criteria, we identified a set of high-priority candidate genes ([Table 2](#tbl2){ref-type="table"} ).Table 2High-Priority Candidate Genes Identified under *Ari* Loci based on Evaluation CriteriaQTLGeneCoding VariantSplice VariantUTR VariantOther Non-coding VariantLung or Immune Tissue ExpressionIAV-Induced Differential ExpressionHaplotype-Specific ExpressionCriteria MetLungBloodLungBlood*Ari1Unc5cl*NANANAyesyesnoyesnoyesnon-coding*Ari2Mis12*NANA3′, 5′yesyesyesnoyesyesnon-coding*Ari2Nlrp1b*MisYesNAyesyesyesyesyesnocoding, non-coding*Ari2Nup88*NANANAyesyesyesyesyesnonon-coding*Ari2Rpain*MisNANAyesyesnoyesyesnonon-coding*Ari2Spns3*SynNANAyesyesyesnoyesnonon-coding*Ari2Wscd1*MisNANAyesyesyesnoyesnocoding, non-coding*Ari3Bcar1*MisNANAyesyesyesyesNANAcoding*Ari3Hydin*MisNANAyesyesyesnoNANAcoding*Ari3Kars*Synyes3′, 5′yesyesyesyesNANAsplice*Ari3Mlkl*NAyesNAyesyesyesyesNANAsplice*Ari3Pkd1l3*NonNANAyesyesnoyesNANAcoding*Ari3Zfhx3*MisNANAyesyesyesyesNANAcoding*Ari4Cc2d2a*NANANAyesyesyesnoyesnonon-coding*Ari4Ldb2*NANANAyesyesyesnoyesnonon-coding*Ari4Prom1*NANANAyesyesyesyesyesnonon-coding*Ari4Tapt1*NANA3′yesyesnoyesyesnonon-coding[^4]

*Ari1* contains 139 genetic elements (e.g., protein-coding genes, large intergenic noncoding RNAs \[lincRNAs\], retained introns, pseudogenes) (25,732 SNPs), which was narrowed to 15 genetic elements (100 SNPs) above the association threshold (LOD \> 3.2) ([Table S7](#mmc1){ref-type="supplementary-material"}), and then to six protein-coding genes (46 SNPs), five of which were expressed in relevant tissues. All of these candidate genes contained non-coding variants, while none of the SNPs resulted in non-synonymous coding changes or splice variants. Analysis of haplotype-specific expression found while none of the candidates showed haplotype-specific expression in the lungs, one gene, unc-5 family C-terminal like (*Unc5cl* or *Zud*), showed haplotype-specific expression in the peripheral blood, making *Unc5cl* the lead candidate gene under the locus.

*Ari2* contains 99 genetic elements (11,236 SNPs), which was narrowed to 40 genetic elements (286 SNPs) above the association threshold (LOD \> 4) ([Table S7](#mmc1){ref-type="supplementary-material"}) and then to 20 protein-coding genes (166 SNPs), 18 of which were expressed in relevant tissues. One of these genes (NOD-like receptors, pyrin domain containing 1B \[*Nlrp1b*\]) had non-synonymous variants and splice variants and showed haplotype-specific expression in the lung. Two genes had both non-synonymous variants and haplotype-specific expression in the lung (WSC domain containing 1 \[*Wscd1*\] and RPA-interacting protein \[*Rpain*\]). Three additional genes under *Ari2* with non-coding variants showed haplotype-specific expression in the lung (spinster homolog 3 \[*Spns3*\], MIS12 kinetochore complex component \[*Mis12*\], and nucleoporin 88 \[*Nup88*\]).

*Ari3* contains 82 genetic elements (14,707 SNPs), which was narrowed to 57 genetic elements (607 SNPs) above the association threshold (LOD \> 2.85) ([Table S7](#mmc1){ref-type="supplementary-material"}) and then to 40 protein-coding genes (565 SNPs), 30 of which were expressed in relevant tissues. Under *Ari3*, there were four genes with non-synonymous coding variants (breast cancer anti-estrogen resistance protein 1 \[*Bcar1*\], HYDIN axonemal central pair apparatus protein \[*Hydin*\], polycystic kidney disease 1 like 3 \[*Pkd1l3*\], and zinc-finger homeobox 3 \[*Zfhx3*\]). There were two additional genes with splice variants (lysyl-tRNA synthetase \[*Kars*\] and mixed lineage kinase domain-like \[*Mlkl*\]). We were not able to evaluate *Ari3* non-coding candidates based on haplotype-specific expression due to a lack of representation of the WSB/EiJ haplotype at *Ari3* in the strains included in the transcriptional dataset.

*Ari4* contains 22 genetic elements (4,899 SNPs), which was narrowed to 16 genetic elements (68 SNPs) above the association threshold (LOD \> 0.597) ([Table S7](#mmc1){ref-type="supplementary-material"}) and then to six protein-coding genes (51 SNPs), all of which were expressed in relevant tissues. Under *Ari4*, 4 genes with non-coding variants showed haplotype-specific expression in the lung (coiled-coil and C2 domain containing 2A \[*Cc2da2*\], LIM-domain-binding protein 2 \[*Ldb2*\], Prominin 1 \[*Prom1*\], and transmembrane anterior posterior transformation 1 \[*Tapt1*\]).

Discussion {#sec3}
==========

The humoral immune response is an important component of protection against viruses such as IAV. However, studying the role of the genetic factors that contribute to regulation of the antibody response is challenging in humans due to confounding demographic and environmental variables, as well as the relatively late stage in infection when the humoral response occurs. To study the role of host genetics in driving the antibody response to IAV, we used a diverse panel of CC-F1s and found that CC mice exhibit high levels of variation in susceptibility to disease as well as the generation and maintenance of specific antibody isotypes and subtypes. In concordance with human studies ([@bib28], [@bib35], [@bib47]), we found strong evidence for genetic control of these traits (median heritability, 44%) and were able to map multiple loci associated with antibody responses.

In addition to genetic mapping, the CC provides a platform for phenotypic discovery and model development. Unique combinations of alleles present in CC mice may present as novel phenotypes, which can provide an opportunity to study interesting disease features and/or more closely model human disease ([@bib51], [@bib53]). We identified multiple CC-F1s with outlier antibody response phenotypes in our investigation, including multiple F1s with persistent IAV-specific IgM responses. Importantly, those F1s with persistent IgM responses were not defective in IAV-specific IgG responses, and some had protective *Mx1* alleles, suggesting that the sustained IgM response was not due to failure in class switching or inability to control viral replication. Notably, two highlighted CC-F1s with persistent IgM responses shared the parental strain CC032, suggesting that genetic contributions from CC032 (independent of *Ari3*, for which CC032 has the low-response haplotype) may be involved in longer lasting IgM responses. Such outlier strains can be used to model these aberrant responses and/or included in future targeted mapping studies (e.g., F2 crosses).

All antibody response measures were driven to varying degrees by genetically variable (e.g., heritable) effects; however, not all phenotypes were mapped to QTL. This issue of "missing heritability" (the inability to identify all the genetic factors that contribute to heritable variation) is prevalent across genetic mapping studies. Missing heritability can be explained by numerous factors, including lack of sufficient power or informative lines to detect variants of small effect, phenotypic heterogeneity (i.e., same phenotype, different cause), complex genetic architecture, and blindness to genetic features such as copy number variants or epigenetic modifications ([@bib38]). More targeted studies, such as 2-strain intercrosses, allow for a more complete discovery of phenotypic modulation with greater power to identify more complex genetic interactions such as epistasis ([@bib17], [@bib53]). Nonetheless, we had sufficient power to identify major loci with effects across our CC-F1 population.

We further investigated our mapped QTLs to identify broader relationships with additional phenotypes to further assess the breadth of effect of each QTL. When testing for further associations with *Ari1*--*Ari4* haplotypes across antibody datasets (IAV, SARS-CoV, and CHIKV), rather than focusing on any individual association, we were interested in robust and persistent trends in correlations across isotypes and/or time points. This is critical due to the differing heritability and potential genetic architecture across isotypes and time points. Therefore, while we did not utilize false discovery rate or multiple-test corrections in assessing these relationships, these trends are indicative of important relationships that merit further study. Furthermore, consideration of these trends, or lack thereof, can provide insight into possible mechanisms by which the genes driving QTL impact the antibody response. *Ari1* showed broad effects on the early antibody response to IAV only and was not associated with antibody response to SARS-CoV or CHIKV, suggesting that it may be involved with specific responses to IAV such as innate immune recognition and response or antigen presentation. *Ari2* showed broad early effects with IAV as well as SARS-CoV-specific responses, suggesting that the underlying gene is involved in early stages of infection or immune response for respiratory pathogens. *Ari3* also showed broad early effects with IAV and a strong correlation with antibody response to CHIKV, though the haplotype effects were in opposing directions for these two different viruses. *Ari4* was most relevant for day 15 antibody response to IAV and also showed strong associations with antibody response to SARS-CoV, suggesting that it may be widely relevant for the development of the humoral response. These broad associations highlight the utility of the CC as a resource to extend analyses into related datasets to gain further understanding of the role of loci across phenotypes while illustrating the need for future work to define the specific mechanisms by which each of these loci affect antiviral antibody response.

In addition to impacting the scope of pathogens for which a QTL may play a role, the mechanisms by which these loci mediate antibody response to primary H1N1 infection is also relevant for their potential to affect antibody response to other strains of IAV or even IAV vaccination. QTLs that are driven by genes involved in early innate response in the lung are more likely to be specific to primary infection and may also be virus-strain specific ([@bib54]). Alternatively, QTLs that appear to be more generally involved in the later humoral response, such as *Ari4*, may be more likely to have a broader effect that is relevant for other IAV strains and vaccination.

Ultimately, the goal of genetic mapping studies is to identify the causal genes and variants driving phenotypic differences. Insights into possible mechanisms gained from analyzing broad associations across an array of phenotypes can help guide selection of candidate genes, along with other considerations such as gene classification, predicted consequence of mutations, expression in relevant tissues, and any known relevance in infection and/or immunity. We leveraged a transcriptional dataset from lungs and blood of CC strains infected with IAV H3N2, which allowed us to assess haplotype-specific expression of candidate genes in the context of the relevant tissue systems. These results were able to help us to narrow our focus on smaller sets of genes (as shown in [Figure 5](#fig5){ref-type="fig"}). However, it is possible that due to disease kinetics, the tissue complexity, and our above-discussed description of strain-differences, this analysis is overly restrictive.

Under *Ari1*, we identified one candidate gene, *Unc5cl* (*Zud*), which showed flu-induced and haplotype-specific expression in the peripheral blood, but not the lungs. While the function of *Unc5cl* is largely unknown, it contains a death domain and has been shown to be involved in the regulation of nuclear factor κB (NF-κB) ([@bib20], [@bib72]). To our knowledge, a role of *Unc5cl* in host response to viral infection has not been evaluated, and this gene presents a clear candidate for additional analysis.

Under *Ari2,* we identified 6 candidate genes (*Mis12, Nup88, Nlrp1b, Rpain, Spns3,* and *Wscd1*). There is no documented role in immunity for *Wscd1* or *Mis12. Rpain* (also known as *RIP* and *HRB*) has been shown to play an important role in the nuclear export of viral ribonucleoproteins (vRNPs) during IAV replication via interaction with the IAV nuclear export protein NS2. *Spns3* is highly expressed in the spleen and thymus, and its paralog, *Spsn2*, has been shown to be important for lymphocyte development and humoral immune response ([@bib45]). *Nup88* has been shown to be important for MX2 inhibition of HIV ([@bib9]), and its *Drosophila* paralog is involved in innate immune activation ([@bib65]). *Nlrp1b* is an inflammasome gene, of which different genetic variants have been shown to play a role in susceptibility to anthrax lethal toxin ([@bib41]), although it has not been previously linked to viral infection.

Under *Ari3*, we identified 6 candidates genes with non-synonymous or splice region variants (*Bcar1, Hydin, Kars, Mlkl, Pkd1l3,* and *Zfhx3*). *Bcar1* and *Zfhx3* have no established role in immunity or viral infection. *Hydin* function is important for ciliary projections and motility, which could affect influenza tropism ([@bib29], [@bib59]). *Kars* (also known as *LysRS*) encodes a tRNA synthetase, which plays a fundamental role in protein translation in addition to acting as a signaling molecule that responds to immunological stimulation ([@bib70]). *Mlkl* encodes a protein that plays a critical role in necroptosis, and its activity is enhanced by interaction with the NS1 protein of IAV ([@bib14]). *Pkd1l3* encodes a calcium channel component and is largely conserved across classical inbred strains but has a unique nonsense mutation in the WSB allele (which drives the QTL effect).

We were unable evaluate haplotype-specific expression for genes under *Ari3* due to a lack of haplotype representation in our transcriptional dataset. However, there are several genes with non-coding variants under the interval that could be considered additional candidates based on precedence in the literature. DEAD box polypeptide 19b (*Ddx19b*) inhibits type I interferon (IFN) and is required for IAV replication via a role in nuclear export of vRNPs ([@bib10], [@bib75]). Dihydroorotate dehydrogenase (*Dhodh*) is involved in pyrimidine synthesis, and DHODH inhibitors have been shown to have strong antiviral activity against influenza and other viruses ([@bib5], [@bib73]). Gamma-aminobutyric acid A receptor-associated protein-like 2 (*Gabarapl2*, also known as *Gate-16*) plays a role in autophagy and IFN-γ-dependent antimicrobial response ([@bib55]). Haptoglobin (*Hp*) is involved in MyD88-dependent inflammation, which plays an important role in primary influenza infection ([@bib57]), and deficiency leads to impaired lymphocyte development and adaptive immune response ([@bib21], [@bib58]). Despite the lack of haplotype-specific expression data, these genes may warrant further evaluation as potential candidate genes under *Ari3.*

Under *Ari4*, we identified 4 candidates of interest: *Lbd2*, *Prom1*, *Cc2da2*, and *Tapt1*. Neither *Lbd2* nor *Prom1* has a documented role in immunity. *Cc2da2* is required for cilia biogenesis, which as previously mentioned may be relevant for influenza tropism ([@bib59], [@bib66]). *Tapt1* is also important for ciliogenesis, and knockdown has been shown to decrease IAV replication ([@bib62], [@bib63]). Notably, multiple candidate genes under the *Ari* loci have roles in ciliary function (*Hydin*, *Cc2da2*, and *Tapt1*). Human patient cohorts have shown co-occurrence of primary ciliary dyskinesia and humoral immunodeficiency, both rare disorders, suggesting a possible common pathophysiological pathway between ciliary function and antibody response ([@bib2]). *Tapt1* has also been shown to be differentially expressed in the context of other respiratory pathogens ([@bib8]) and was identified in a gene set associated with increased HA inhibition and neutralization titers following influenza vaccination ([@bib48]), further supporting a potential role for this gene in driving *Ari4.*

Following candidate identification, validation presents new challenges. This is exemplified by *Ari2*, under which *Nlrp1b* was identified as the strongest candidate gene, carrying haplotype-specific coding variants predicted to be strongly deleterious to the encoded innate immune sensor. However, analysis of this gene and interpretation of expression data is challenging because of the newly described genetic complexity of the locus; multiple *Nlrp1* paralogs and haplotypes sort across mouse strains and have not been fully characterized (e.g., WSB/EiJ mice carry 5 *Nlrp1* paralogs, only 2 of which are shared with the reference C57BL/6J) ([@bib34]). Upon IAV infection, *Nlrp1b* knockout mice did not show significant differences in antibody response ([Figure S5](#mmc1){ref-type="supplementary-material"}). While this lack of phenotype might suggest that *Nlrp1b* is not causal for the *Ari2* phenotype, it is equally likely that the specific *Nlrp1b* allelic variant in the CC, or one of the *Nlrp1* paralogs, is responsible for the effect of *Ari2*. Continued work to deconvolute the mouse genome across genetically diverse strains, as well as advances in molecular and genetic tools such as CRISPR, will facilitate follow-up analyses on such complex loci.

Other potential challenges remain in the identification and validation of genes that regulate the antibody response to IAV. Notably, we studied IAV exposure in naive animals, whereas prior infection (especially with IAV) is a large factor in shaping the humoral immune response in humans ([@bib31]). Nonetheless, we identified multiple loci with genes that overlap with human mapping studies of antibody response or influenza infection. *Ari1* contains kinesin family member 6 (*Kif6*), which was identified in a human study of antibody response to smallpox vaccination ([@bib47]). *Kif6* did not meet our formal candidate criteria as its coding variant was synonymous and it did not show haplotype-specific expression in the dataset that we utilized. Additionally, *Ari2* contains two genes that were identified in a human study of severe pneumonia associated with H1N1 influenza infection ([@bib76]), *Rpain* and complement component 1 Q subcomponent-binding protein (*C1qbp*), a high-affinity receptor for the complement protein C1q that is important for dendritic cell maturation ([@bib16]). While *Rpain* met our criteria as a candidate gene, and is therefore a high-priority candidate for additional analysis, *C1qbp1* had a non-coding variant, but did not show haplotype-specific expression in the lungs or blood. Lastly, as noted above, *Tapt1* under *Ari4* has been associated with variation in antibody responses to IAV vaccination in humans ([@bib48]), making this gene a high-priority candidate for additional study. While not all of these genes made it through our formal selection criteria, this concordance between loci mapped in our study and in human studies demonstrates the translational relevance of our work, and we are optimistic that other loci mapped here could be validated and important in humans.

Conclusions {#sec3.1}
-----------

The magnitude and kinetics of the antibody response to IAV varies greatly across a genetically diverse set of CC-F1 mice. These differences, which did not widely correlate with general susceptibility to IAV-induced disease, were leveraged to map 23 QTLs associated with variation in specific antibody isotypes across time points. Multiple significant and suggestive QTLs were identified, including *Ari1*--*Ari4*, which likely drive variation in IAV-specific antibody response through different mechanisms. *Ari* loci also showed effects on the antibody response to SARS-CoV and CHIKV, suggesting that these QTLs are broadly important for antibody response to multiple pathogens. Candidate genes for *Ari* loci have been identified and show overlap with genes identified in human studies. Overall, our findings demonstrate that multiple independent loci regulate the magnitude, kinetics, and composition of IAV-specific antibody. These results further demonstrate the utility of the CC for modeling how host genetic variation shapes pathogen-specific immunity and open the door to more robust modeling of the complex interplay between genetics and environment in promoting protective adaptive immune responses to pathogens.

STAR★Methods {#sec4}
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Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**HRP goat anti-mouse IgMSouthern Biotech1020-05; RRID: [AB_2794201](nif-antibody:AB_2794201){#interref100}HRP goat anti-mouse IgG1Southern Biotech1070-05; RRID: [AB_2650509](nif-antibody:AB_2650509){#interref105}HRP goat anti-mouse IgG2aSouthern Biotech1080-05; RRID: [AB_2734756](nif-antibody:AB_2734756){#interref110}HRP goat anti-mouse IgG2bSouthern Biotech1090-05; RRID: [AB_2794521](nif-antibody:AB_2794521){#interref115}HRP goat anti-mouse IgG2cSouthern Biotech1079-05; RRID: [AB_2794466](nif-antibody:AB_2794466){#interref120}HRP goat anti-mouse IgG3Southern Biotech1100-05; RRID: [AB_2794573](nif-antibody:AB_2794573){#interref125}HRP goat anti-mouse IgGSouthern Biotech1030-05; RRID: [AB_2619742](nif-antibody:AB_2619742){#interref130}Biotin-conjugated goat anti-mouse IgMSouthern BiotechRRID: [AB_2794242](nif-antibody:AB_2794242){#intref0010}Biotin-conjugated goat anti-mouse IgGSouthern BiotechRRID: [AB_2794296](nif-antibody:AB_2794296){#intref0015}anti-CHIKV CHK-11 mAbDiamond laboratory[@bib49]HRP-conjugated goat anti-mouse IgGSouthern BiotechRRID: [AB_2619742](nif-antibody:AB_2619742){#intref0020}**Bacterial and Virus Strains**Influenza A/CA/04/09 (H1N1)Laboratory of Yoshihiro KawaokaN/AMouse-adapted SARS-CoV MA15[@bib52]N/AMouse-adapted A/Hong Kong/01/68 (H3N2)[@bib18]NACHIKV strain 181/25Dermody laboratory[@bib37]CHIKV strain SL15649[@bib42]icCHIKVSL15649**Biological Samples**C57BL6/J immune seraThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**RNAlaterApplied Biosystems/AmbionAM7021TrizolInvitrogen15596018HA antigenBEI ResourcesNR13691SARS S proteinBEI ResourcesNR722TMB substrateThermoFisher Scientitic34028OPD powderSigmaP9029KPL TrueBlue SubstrateSeraCare5510-0030Streptavidin-HRPSouthern Biotech7100-05**Critical Commercial Assays**miRNeasy mini kitQIAGEN217004RNeasy Midi KitQIAGEN75144SENSE mRNA-Seq Library Prep Kit for Ion TorrentLexogen00624Ion Torrent PGM 314 chipLife Technologies4482261High Sensitivity DNA chipLife Technologies50674626Ion OneTouch 2 SystemLife TechnologiesINS1005527Ion P1 ChipLife TechnologiesA26770Whole mouse genome microarrayAgilent026655**Deposited Data**Antibody response to IAV A/CA/04/09 in CC-F1sThis paper; Mendeley Data[https://doi.org/10.17632/kxr3t8n384.1](10.17632/kxr3t8n384.1){#intref0025}Antibody response to SARS-CoV in CC-F1sThis paper; Mendeley Data[https://doi.org/10.17632/kxr3t8n384.1](10.17632/kxr3t8n384.1){#intref0030}Antibody response to CHIKV in CC-RIsThis paper; Mendeley Data[https://doi.org/10.17632/kxr3t8n384.1](10.17632/kxr3t8n384.1){#intref0035}RNaseq raw reads and normalized count matrix (lung)GEO (Gene Expression Omnibus)GSE136748Gene Expression array normalized expression matrix (blood)GEO (Gene Expression Omnibus)GSE110384**Experimental Models: Cell Lines**Vero E6 cellsATCCCRL-1586MDCK cellsATCCCCL-34MDCK II cellsATCCCRL-2936HEK293T cellsATCCCRL-3216Vero cellsATCCCCL-81**Experimental Models: Organisms/Strains**Collaborative Cross MiceUNC SGCFSupplemental file**Oligonucleotides**Forward primer for detection of IAV viral load: GACCRATCCTGTCACCTCTGAC[@bib44]WHO_CDC_Influenza A_pandemic H1N1 testReverse primer for detection of IAV viral load: AGGGCATTYTGGACAAAKCGTCTA[@bib44]WHO_CDC_Influenza A_pandemic H1N1 testProbe for detection of IAV viral load: TGCAGTCCTCGCTCACTGGGCACG (FAM)[@bib44]WHO_CDC_Influenza A_pandemic H1N1 testEukaryotic 18S rRNA Endogenous Control (VIC/MGB probe, primer limited)Applied Biosystems4319413E**Software and Algorithms**DOQTL[@bib15]N/AR[@bib50]N/Acckit<https://github.com/kenoll/cckit>N/AVariant Effect Predictor[@bib40]N/AC.T.L. Biospot SoftwareCellular Technology LimitedV6.6.8FastQC[@bib1]<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>Trimgalore[@bib27]<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>STAR aligner[@bib11]<http://github.com/alexdobin/STAR>RsubRead[@bib33]<http://bioconductor.org/packages/release/bioc/html/Rsubread.html>DESeq2[@bib36]<http://bioconductor.org/packages/release/bioc/html/DESeq2.html>sva[@bib30]<http://bioconductor.org/packages/release/bioc/html/sva.html>**Other**MRCA probabilities[@bib60]N/A
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### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mark T. Heise (<mark_heisem@med.unc.edu>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

The antibody datasets generated and used during this study are available at Mendeley Data (<https://dx.doi.org/10.17632/kxr3t8n384.1>). Lung and blood expression datasets are available through the Gene Expression Omnibus (GSE136748, [GSE110384](ncbi-geo:GSE110384){#intref0085}).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Ethics statement {#sec4.3.1}

#### University of North Carolina at Chapel Hill {#sec4.3.1.1}

Mouse studies were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All mouse studies at UNC (Animal Welfare Assurance \#A3410-01) were performed using protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC) in a manner designed to minimize pain and suffering in infected animals. Any animals that exhibited severe disease signs was euthanized immediately in accordance with IACUC approved endpoints.

#### Helmholtz Centre for Infection Research {#sec4.3.1.2}

All experiments in mice were approved by an external committee according to the national guidelines of the animal welfare law in Germany (BGBl. I S. 1206, 1313 and BGBl. I S. 1934). The protocol used in these experiments has been reviewed by an ethics committee and approved by the relevant authority, the 'Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany' (Permit Numbers: 33.9.42502-04-051/09 and 3392 42502-04-13/1234).

### Mice {#sec4.3.2}

#### IAV H1N1 {#sec4.3.2.1}

Mice from 64 CC strains were purchased from the UNC Systems Genetics Core Facility (SGCF) between July 2012 and July 2016. Female mice were generated from 116 CC-F1 crosses between these 64 CC strains (see [Data S1](#mmc2){ref-type="supplementary-material"} for full list). All mice were housed in a specific pathogen free facility under standard conditions (12hr light/dark, food and water *ad libitum*) at UNC Chapel Hill. Female mice of 8-12 weeks of age at time of experiment were used. *Nlrp1b* KO and C57BL/6J mice were purchased from Jackson Laboratories and bred in our colony at UNC Chapel Hill. F1 or F2 heterozygous animals were bred to generate a single experimental cohort with littermate controls. Male and female mice were used and infected when mice were between 9-11 weeks of age.

#### IAV H3N2 {#sec4.3.2.2}

Mice from 11 CC strains (see [Data S1](#mmc2){ref-type="supplementary-material"} for full list) were received from the UNC SGCF and then bred in the animal facility of the Helmholtz Centre for Infection Research, Braunschweig under specific pathogen free conditions. Female mice of 8-12 weeks of age at time of experiment were used.

#### SARS-CoV {#sec4.3.2.3}

Mice from 64 CC strains were purchased from the UNC SGCF between July 2012 and July 2016. Female F1 mice were generated from 116 CC-F1 crosses between these 64 CC strains (see [Data S1](#mmc2){ref-type="supplementary-material"} for full list). All mice were housed in a BSL-3 facility at UNC Chapel Hill. Mice were 8-12 weeks of age at time of experiment.

#### CHIKV {#sec4.3.2.4}

Female mice from 64 CC strains (see [Data S1](#mmc2){ref-type="supplementary-material"} for full list) were housed under BSL-3 conditions at UNC Chapel Hill. Mice were 6-7 weeks old at time of experiment.

### Cell lines {#sec4.3.3}

HEK293T (ATCC) were used for the propagation of IAV H1N1. MDCK cells (ATCC) were used for the amplification and titration of IAV H1N1. MDCK II cells (ATCC) were used for the titration of IAV H3N2. Vero E6 cells (ATCC) were used for the titration of SARS-CoV. Vero cells (ATCC) were used for the titration of CHIKV and FRNT50 assays. All cells were maintained at 37°C in standard growth media. Serum-free media was used for propagation, amplification, and titration of IAV.

Method Details {#sec4.4}
--------------

### Virus {#sec4.4.1}

#### IAV H1N1 {#sec4.4.1.1}

Influenza A/CA/04/09 (H1N1) was generated by multi-plasmid transfection of HEK293T cells followed by 48 hour amplification and titration in MDCK cells as described previously ([@bib43]).

#### IAV H3N2 {#sec4.4.1.2}

Mouse-adapted A/Hong Kong/01/68 (H3N2) virus was originally obtained from Otto Haller, University of Freiburg ([@bib18]). Virus was propagated as described previously ([@bib69]). Titer was determined by focus forming unit assay (FFU/ml) in Madin-Darby Canine Kidney II (MDCK) cells (ATCC).

#### SARS-CoV {#sec4.4.1.3}

Recombinant mouse-adapted SARS-CoV MA15 (mouse adapted SARS-CoV Urbani strain) was propagated and titered on Vero E6 cells. All experiments were performed in a certified BSL-3 laboratory.

#### CHIKV {#sec4.4.1.4}

The SL15649 clinical isolate of CHIKV was derived from the pMH56.2 infectious clone and titered on Vero cells, as described previously ([@bib42]).

### Infections {#sec4.4.2}

#### IAV H1N1 {#sec4.4.2.1}

Mice were lightly anesthetized via isoflurane inhalation and infected intranasally with either 5000 focus forming units (FFU) of influenza A/CA/04/09 in 50μL PBS or PBS only (mock-treatment). Approximately 3 mice per F1 per time point were infected with IAV. Animals were measured daily for weight loss and monitored for mortality and clinical disease scores. At 2, 4, 7, 10, 15, or 45 days post-infection, animals were euthanized via isoflurane overdose and bilateral thoracotomy. Lungs for viral load were collected at day 2 post-infection and stored in RNAlater (Applied Biosystems/Ambion, Austin, TX) at −80°C after 1 day at 4°C. Blood was collected by terminal bleed, and serum was aliquoted and stored at −40°C or −80°C. For *Nlrp1b* studies, all mice were infected with IAV and serum was collected by submandibular bleed at day 10 post-infection.

#### IAV H3N2 {#sec4.4.2.2}

Mice were anesthetized by intra-peritoneal injection with Ketamine/Xylazine (85% NaCl (0.9%), 10% Ketamine, 5% Xylazine) and infected intranasally with 20μl virus solution (10 FFU) in PBS or PBS only (mock-treatment). 3-4 mice per strain per time point and treatment were infected. Body weight, survival and well-being of mice were monitored. Lungs were harvested from sacrificed mice at days 3 and 5 post-infection. Blood was collected by retro-orbital bleed at days 3, 5, and 8 post-infection.

#### SARS-CoV {#sec4.4.2.3}

Mice were lightly anesthetized via isoflurane inhalation and infected intranasally with 5x10^3^ plaque forming units (PFU) of MA15 in 50μL PBS or PBS only (mock-treatment). Approximately 3 mice per F1 per time point were infected with SARS-CoV. Animals were measured daily for weight loss and monitored for mortality and clinical disease scores. At 7, 15, or 29 days post-infection, animals were euthanized via isoflurane overdose and bilateral thoracotomy. Another group of animals was re-challenged at day 28 post-infection, and euthanized at day 32 (4 days post-re-challenge). Blood was collected by terminal bleed, and serum was aliquoted and stored at −80°C.

#### CHIKV {#sec4.4.2.4}

Mice were infected with 100 PFU of CHIKV SL15649 in a 10μl volume via the subcutaneous route in the left rear footpad, or PBS alone (mock treatment). Three mice per group were infected and two per group received mock treatment. Mice were euthanized on day 7 post infection and serum was collected and stored at −80°C.

### Viral load measurement {#sec4.4.3}

Lung tissue was thawed on ice and transferred to Trizol (Invitrogen, Carlsbad CA) preceding homogenization and RNA extraction using the QIAGEN miRNeasy mini kit (QIAGEN, Hilden, Germany, 217004). One-step RT-PCR was performed to quantify IAV (F: GACCRATCCTGTCACCTCTGAC. R: AGGGCATTYTGGACAAAKCGTCTA, Probe: TGCAGTCCTCGCTCACTGGGCACG, Reporter: FAM) and 18S (4319413E, Applied Biosystems, Foster City, CA) in duplex. Delta CT values were calculated as the difference between IAV and 18S CT values.

### Antibody measurement {#sec4.4.4}

#### IAV H1N1 and SARS-CoV ELISA {#sec4.4.4.1}

IAV hemagglutinin (HA)-specific and SARS-CoV spike-specific antibody were quantified by ELISA. 96 well flat-bottom plates were coated with HA antigen (BEI Resources, Mannassas, VA, NR13691) or SARS S protein (BEI Resources NR722) (diluted in carbonate buffer (0.32M Na~2~C0~3~, 0.68M NaHCO~3~) to 1 μg/mL). Half-log serum dilutions (10^2^ to 10^5.5^) were prepared in wash buffer (0.033% Tween-20 in PBS), added to coated plates, and incubated overnight in a humidified chamber at 4°C. Plates were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Southern Biotech, Birmingham, AL, HRP conjugated goat anti-mouse, IgM = 1020-05, IgG1 = 1070-05, IgG2a = 1080-05 pooled with IgG2c = 1079-05, IgG2b = 1090-05, IgG3 = 1100-05, Total IgG = 1030-05) for approximately 2 hours at 4°C. IAV plates were washed and developed in the dark for 30 minutes at room temperature with citrate substrate (.05M sodium citrate, 0.05M citric acid, 1mg/mL OPD, 0.216% hydrogen peroxide), then stopped with sodium fluoride (0.1M) and read immediately at 450nm. SARS-CoV plates were washed and developed in the dark for 30 minutes with 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (ThermoFisher Scientific, Waltham, MA, 34028), then stopped with HCL (0.2M) and read immediately at 450nm. Background-subtracted OD measurements were set against dilution factors to calculate area under the curve (AUC) values for each sample and isotype. AUC was determined to be the most inclusive measure to robustly captured the dynamic range of antibody levels across our sample set, and performed better than other measurements such as half maximal or lowest positive titer. To monitor consistency across assays, C57BL6/J immune sera as well as serum samples from CC-F1s that were repeated across multiple cohorts were measured multiple times alongside different sets of experimental samples.

#### CHIKV ELISA {#sec4.4.4.2}

CHIKV-specific antibodies in mouse sera were measured using a virion-based ELISA as described ([@bib19]). CHIKV strain 181/25 grown in serum-free media (VP-SFM) was concentrated, suspended in PBS, and was adsorbed to a 96-well Immulon 4HBX plate (1.25 × 10^8^ particles/well). Serum samples were serially diluted and added to the plate. Bound antibody was detected using biotin-conjugated goat anti-mouse IgM or IgG antibodies, followed by HRP-conjugated streptavidin, and detection with TMB substrate (Sigma-Aldrich, St. Louis, MO). Endpoint titers were defined as the reciprocal of the last dilution to have an absorbance four standard deviations greater than background. Blank wells receiving no serum were used to quantify background signal.

#### CHIKV Focus Reduction Neutralization Test (FRNT) {#sec4.4.4.3}

For FRNT assays, Vero cells were seeded in 96-well plates. Serum samples were heat-inactivated and serially diluted in DMEM/F12 medium with 2% FBS in 96-well plates. Approximately 100 focus-forming units (FFU) of virus stock (CHIKV strain SL15649) was added to each well and the serum plus virus mixture was incubated for 1h at 37°C. At the end of 1h, medium was removed from Vero cells and serum sample plus virus mixture was added for 2 h at 37°C. After 2 h, sample was removed and cells were overlaid with 0.5% methylcellulose in MEM/5% FBS and incubated 18h at 37°C. Cells were fixed with 1% PFA and probed with 500 ng/mL of anti-CHIKV CHK-11 mAb ([@bib49]) diluted in 1X PBS/0.1% saponin/0.1% bovine serum albumin (BSA) for 2h at room temperature. After washing, cells were incubated with HRP-conjugated goat anti-mouse IgG for 1.5-2 h at room temperature. After washing, CHIKV-positive foci were visualized with TrueBlue substrate and counted using a CTL Biospot analyzer and Biospot software (Cellular Technology, Cleveland, OH). Percent infectivity was calculated compared to a virus only (no serum) control. The FRNT50 value was defined as the reciprocal of the last dilution to exhibit 50% infectivity.

### Expression analysis {#sec4.4.5}

#### Lung expression {#sec4.4.5.1}

Whole lungs were stored in RNAlater solution (QIAGEN, Hilden, Germany), kept at 4°C for one day and subsequently stored at −20°C. RNA was isolated using QIAGEN Midi Kit. RNA quality was controlled on a 2100 Bioanalyzer Instrument (Agilent, Santa Clara, CA). All RNA samples had a RNA Integrity Number (RIN) of ≥ 9.5. 3 to 6 independent biological replicates were selected for each time point for subsequent RNA sequencing. 500ng of total RNA was used to prepare libraries for sequencing using the Lexogen SENSE mRNA-seq library kit for Ion Torrent. Libraries amplified for 11 cycles as the final step of library preparation. Before sequencing, 1ul aliquots of this material was pooled and sequenced on an Ion Torrent PGM 314 chip. Barcode quantification data from the PGM were used to balance the barcodes for final pooling before sequencing. Following this final pooling, the library pools were sized to a target size of 260bp on a Pippin Prep instrument using the 2% Pippin Agarose gel. The sized libraries were examined on an Agilent High Sensitivity DNA chip, quantified using real-time PCR, and used to prepare spheres using a One-Touch 2 device. These spheres were then sequenced on an Ion Torrent Proton sequencer with a P1 chip. The mean number of reads per sample was 24 million. Reads were quality checked with package FastQC ([@bib1]), then trimmed using Trimgalore ([@bib27]). Trimmed reads were mapped to mouse genome annotation mm10 (build 38.1) using STAR aligner ([@bib11]). Further analysis and visualization of expression data was performed using the R software package. Mapped reads were feature counted (per gene) using RsubRead ([@bib33]). Raw counts from mouse genome and virus mapping were then combined and normalized using DESeq2 ([@bib36]). After normalization, single extreme outlier points were razorized, log~2~ transformed, normalized expression levels were then batch corrected using package sva ([@bib30]). Extreme outlier samples were identified in principle component analyses and removed. For each group, 3 to 4 replicates were retained. Log~2~ transformed, normalized and batch corrected expression levels were outputted for further use.

#### Blood expression {#sec4.4.5.2}

Analysis of expression data from blood was previously described ([@bib25]). Briefly, blood was collected for RNA isolation at multiple time points (days 3, 5, and 8) post-infection by retro-orbital bleed. RNA was isolated, transcribed into cDNA, amplified with incorporation of cyanine 3-labeled CTP, and hybridized to a whole mouse genome microarray (Agilent 026655).

### Candidate selection {#sec4.4.6}

All genetic elements under each QTL were first narrowed by choosing only those containing SNPs above the association testing threshold. Association testing was performed via the assoc.map() function in DOQTL by imputing Sanger SNPs onto the CC genome builds, and thresholds were set independently for each QTL. Candidate SNPs were then run through the Ensembl Variant Effect Predictor ([@bib40]) to determine the genetic classification of the affected gene as well as the predicted consequence of the SNP itself. We selected variants in protein-coding genes only and then filtered to genes expressed in the lung, thymus, and/or spleen. Coding variants were further considered if they were predicted to have a functional consequence on the protein product (e.g., missense versus synonymous variant). Non-coding variants were further considered if haplotype-specific expression differences were observed in lung and/or blood. Genes with coding and/or non-coding variants that met these criteria were included in our final list of candidate genes.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Heritability {#sec4.5.1}

To determine heritability for single time point measurements, we fit the following linear model:$$Phenotype \sim CC - F1 + \varepsilon$$We averaged intraclass correlation \[(MS~CC-F1~ - MS~ε~)/(MS~CC-F1~ + (N-1)MS~ε~)\] and coefficient of genetic determination \[ (MS~CC-F1~ - MS~ε~)/(MS~CC-F1~ + (2N-1)MS~ε~) \] values, using N = 3 as a representative value for group size across all CC-F1s.

### Kinetics {#sec4.5.2}

Values for between-time point antibody measurements were determined by averaging raw AUC values for each CC-F1, then calculating ratios of between adjacent time points (day 10/day 7, day 15/day 10, day 45/day 15) for each isotype. Given only one calculated measurement per time point per CC-F1, heritability and effect size could not be calculated for between-time point phenotypes.

### Normalization {#sec4.5.3}

QTL mapping assumes that phenotypic data is normally distributed. Data for each isotype and time point combination varied in distribution, and therefore were normalized independently based on box-cox transformation values. Normalized single-time point measurements were averaged per CC-F1 preceding QTL mapping.

### Genetic mapping {#sec4.5.4}

We conducted genetic mapping using the DOQTL (1.18.0) ([@bib15]) package in the R statistical environment ([@bib50]). Collaborative Cross genomes are best represented as a 36-state probability matrix (where at each marker, the values indicate the likelihood that a mouse from that strain has a given homozygous (n = 8) or heterozygous (n = 28) diplotype). We took the 36-state probability files from the CC Most Recent Common Ancestors (MRCAs) consensuses for each strain and simplified these to 8-state probabilities as previously described ([@bib60]). For each CC-F1, we averaged the 8-state probabilities of the two parent CC strains. This approach is the most accurate for F1 animals, as they will receive only one allele from each parent CC strain. For genetic mapping in DOQTL, a multiple regression is run at each marker, running the phenotype of interest against haplotype probabilities for each strain. LOD scores are calculated based on the improvement of fit in this model compared to a null model considering only covariates and kinship. To determine significance, permutation tests were run in which phenotype and genotype data are shuffled without replacement to generate a series of null LOD scores, of which the highest is archived. Based on 1000 permutations, we determined null distributions. We calculated p value scores by empirical cumulative distribution function, comparing the maximum LOD score for a QTL to the distribution of null permutations. QTL regions were determined using a 1.5LOD drop interval.

### Haplotype scoring {#sec4.5.5}

Once loci were identified, haplotype groups for each QTL were manually determined based on visualization of haplotype effect plots. Additive haplotype scores for CC-F1s were computed by combining the haplotype scores for the dam and sire of the F1. CC-F1s were dropped from analyses if either the dam or sire had heterozygosity or recombinations within the locus between founder haplotypes with differing effect scores. In the case of *Ari2*, there was an insufficient number of representative crosses for one haplotype effect group (only two F1s with an additive score of 0), and therefore this group was dropped from analyses.

### Phenotypic variance {#sec4.5.6}

Effect sizes were computed by linear regression:$$Phenotype \sim dam\ haplotype + sire\ haplotype + CC - F1 + \varepsilon$$We calculated \[(Sum of Squares~dam~ + SS~sire~) / (SS~dam~ + SS~sire~ + SS~CC-F1~)\]. QTL effect size was multiplied by trait heritability to determine the percentage of total phenotypic variation explained by the QTL.

### Phenotypic correlations {#sec4.5.7}

Correlations between *Ari* loci and other phenotypes were calculated by running the following mixed effect linear models and comparing goodness of fit between them with an ANOVA test to determine a p value. Haplotype ((0, 1) or (0, 1, 2)) was included as a numeric variable representing the dosage of the allele associated with the high response.$$Phenotype \sim CC - F1 + \varepsilon$$ $$Phenotype \sim additive\ haplotype\ score + CC - F1 + \varepsilon$$To determine correlations with weight loss, *Mx1* haplotype was included in both models:$$Phenotype \sim additive\ Mx1\ haplotype\ score + CC - F1 + \varepsilon$$ $$Phenotype \sim additive\ Mx1\ haplotype\ score + additive\ haplotype\ score + CC - F1 + \varepsilon$$To determine correlations between weight loss and antibody, we ran similar models with antibody measurement values in place of haplotype scores. Since many animals did not reach maximal weight loss until after day 7, only animals from time points 10-45 were included in these models.$$Phenotype \sim additive\ haplotype\ score + CC - F1 + \varepsilon$$ $$Phenotype \sim additive\ Mx1\ haplotype + antibody\ measurement + CC - F1 + \varepsilon$$

Differential expression analysis {#sec4.6}
--------------------------------

Goodness of fit between the following mixed linear models was compared using an ANOVA test to determine IAV-specific (models 1&2) and haplotype-specific (models 2&3) expression.1Gene expression ∼CC-F1 + ε2Gene expression ∼day post-infection + CC-F1 + ε3Gene expression ∼day post-infection + haplotype score + CC-F1 + ε
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